EAPCI Column

DOI:

EAPCI Focus on the EAPCI Scientific Programme and Congress Committee

What is the role of the committee?

For the 2022-2024 term, my Co-Chair Professor Nicole Karam and I, along with the EAPCI Scientific Programme and Congress Committee members, have defined our goal as serving the unmet educational needs of the interventional community. This was to be achieved by providing platforms for the interventional community to share scientific achievements. We found it also very important to create bridges and links to other subspecialities and European Society of Cardiology (ESC) working groups.

How does the EAPCI Scientific Programme and Congress benefit the interventional cardiologist?

As stated in its name, the EAPCI Scientific Programme and Congress Committee has the task of designing and managing the scientific content of EAPCI events. Above all, this includes EuroPCR, PCR London Valves and EAPCI sessions at the ESC Congress. Beyond this, EAPCI has been present at several national and international congresses and meetings within Europe from Germany to Bulgaria, as well as worldwide from Egypt to China. Our Committee has developed joint sessions with several national cardiac societies, in synergy with EAPCI Young Committee. This has enhanced EAPCI visibility at national level, as well as induced new channels of cooperation.

Parallel to that, our Committee has been responsible for coordinating multiple online events and webinars, which have become available over the year, covering various topics, often in collaboration with other subspecialities.

What has been the biggest achievement of your committee?

I do not believe that we could underline one single big achievement. I would instead emphasise that the Committee kept its main objective continuously in focus and made great efforts to follow its mission. We believe the last two years' term has been a fruitful collaboration of this great team of committee members. This has resulted in development and initiation of great session proposals for the main congresses; EAPCI has started proactively collaborating with national societies all over the globe; and last but not least the webinar catalogue now contains a stunning list of programmes.

How can EAPCI members becoming involved in the work of the Scientific Programmme and Congress Committee?

EAPCI is eager to connect with national societies. This is why we have been present at numerous national meetings in collaboration with local societies. Such connections are mostly initiated by local EAPCI members, who share the idea that such networks are beneficial for both parties, but mostly for the interventional community. Of course, such events are also good platforms to extend the network and to identify future active members of the EAPCI committees.

Volume 20 Number 14
Jul 15, 2024
Volume 20 Number 14
View full issue

Suggested by Cory

Editorial

10.4244/EIJ-E-25-00022 Sep 15, 2025
An ongoing quest to discern the optimal antithrombotic therapy after TAVI
Hayashida K and Iwata J
free

Translational research

10.4244/EIJ-D-24-01000 Sep 15, 2025
DurAVR – a novel biomimetic balloon-expandable transcatheter valve for TAVI, valve-in-valve TAVI and redo-TAVI
Meier D et al
open access

Research Correspondence

10.4244/EIJ-D-25-00255 Sep 15, 2025
Redo-TAVI with the ACURATE platform for failure of short-frame transcatheter heart valves
Tarantini G et al

Original Research

10.4244/EIJ-D-24-01066 Sep 15, 2025
VARC-HBR criteria validation in TAVI patients on oral anticoagulation
Overduin D et al

Editorial

10.4244/EIJ-E-25-00038 Sep 15, 2025
Evolving cutoff values for optimising left main stenting with intravascular imaging
de la Torre Hernandez J
free

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free

Flashlight

10.4244/EIJ-D-25-00121 Sep 15, 2025
Calcium mapping by 3DStent technology
Amabile N and Benamer H
Trending articles
56.1

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
56.1

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
51.65

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free
28.25

Clinical research

10.4244/EIJ-D-19-01006 Aug 7, 2020
Coronary collaterals and myocardial viability in patients with chronic total occlusions
Schumacher S et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved